Technology is making rapid advances, and you are part of those breakthroughs. What will you need in a next-generation sequencing company? Proven, best-in-class sequencing technology that allows you to continually innovate and scale as needs change. Instruments with application flexibility and user-friendly bioinformatics tools to help you make sense of the data. And a partner that offers industry-leading support and service.
Leaders turn to Illumina technology for the high-quality sequencing data our instruments produce. They’ve done so for decades. With more than 90% of the world’s sequencing data generated by Illumina sequencing by synthesis (SBS) chemistry,1 and > 17,000 active Illumina sequencers deployed globally, our solutions enable our customers to make discoveries that were unimaginable even a few years ago.
Illumina has a proven track record of genomics solutions that empower researchers to perform studies at the throughput, scale, and price that meets their research objectives. We keenly pursue innovation with ease-of-use and sustainability in mind, and prioritize our internal R&D, continually competing against ourselves to create even better products.
Your next-generation sequencing provider should support a broad range of existing applications and also give you the flexibility to address emerging ones. With instrument options ranging from smaller footprint benchtop systems to larger systems capable of 6 TB of data and improved economics, we have both the flexibility and the power for diverse applications.
Here are some examples of applications Illumina supports that are helping drive genomic breakthroughs:
Decades of experience as an NGS provider, vast global reach, support across countries and languages, and data transparency help us quickly connect and support resources to fight this pandemic.
Using NGS, single-cell RNA-Seq can uncover cellular differences often masked by bulk sampling methods. Explore individual cells to understand cellular subpopulation responses to environmental cues.
NGS is part of an effort to transform drug discovery using big data in a multiomics approach to examine trends in disease states and identify new targets.
When you choose Illumina as your sequencing company, we don’t just place an instrument in your lab. It’s the beginning of a relationship. We provide service and support to get you results. Our technical support lines are staffed with experts, many with PhDs, and we have an extensive library of free online training resources.
Our field service staff goes the extra mile—such as placing machines into Wuhan, China for the first sequencing of the coronavirus.2 We enabled Sri Lanka’s first fully sequenced COVID-19 genome. And we’re working to improve NGS access in Africa.
Time to analysis is key. You don’t want software that takes days to process your data. With Illumina as your sequencing company, you have access to the DRAGEN Bio-IT platform. It offers award-winning accuracy, ultra-rapid secondary analysis, user-friendly cloud or on-premise options, and analysis of a whole human genome in 25 min.
You’ll also want to consider how easy it is to use your NGS company’s analysis solutions. Are they integrated into the instrument? Do they take you seamlessly from sample to report? Or will you need to learn bioinformatics or hire a bioinformatician?
“We have a local DRAGEN server that was easy to implement. We were up and running quickly and found that it isn’t difficult for us to support...we have been able to reduce our data analysis costs by 25–30% on a per-sample basis, including the cost of the physical server over a two-year timeline...”
Alexander Bisignano, CEO of Phosphorus
To ensure you can scale efectively, you’ll want an NGS company with their own library prep automation solutions or one who has partnerships providing this expertise. We work with leading automation vendors to develop automated methods for Illumina kits, eliminating the time and effort needed to develop your own method.View Automation Solutions
The first confirmed case of COVID was run on an Illumina iSeq 100 System.2 The first complete SARS-CoV-2 genome was sequenced using the Illumina MiSeq System.3 99% of SARS-CoV-2 genomes have been sequenced on Illumina systems. There’s a reason lllumina SBS is the preferred technology to power modern science.
Over ~250,000 publications feature Illumina sequencing technology, with thousands of publications in top tier journals. You’re joining a well-established community of researchers.Explore Publication Reviews
NextSeq 1000 and NextSeq 2000 Systems are flexible enough to explore current and emerging applications like single cell, whole exome, and RNA. This easy-to-use system has on-board informatics accessible to both new and expert users. It features 6x faster secondary analysis through the DRAGEN Bio-IT Platform. And the breakthrough system design uses a recyclable reagent cartridge for sustainability.Learn More
“In terms of throughput, in terms of reliability, in terms of accuracy--it was very clear that we selected Illumina as the best provider”
Dr. Szilard Voros, CEO of Global Genomics Group
A clinical metagenomics approach based on Illumina NGS led to the initial detection of the SARS-CoV-2 virus. This approach also accelerated test and vaccine development.
An interdisciplinary team uses Illumina NGS to advance single-cell genomics and identify genetic circuits critical to understanding human health and disease.
Illumina NGS is part of a visionary approach integrating imaging, multiomic technologies, and big data. The goal is to uncover novel diagnostic and therapeutic targets for common chronic diseases.
Contact us today
These resources cover key topics in NGS and are designed to help you plan your first experiment.
Explore our technologies, get training, find software, plan experiments, purchase, and get support.